Wegovy Trial in Children as Young as 6 Finds Smaller Height Gains

By Rinor

|

18 November 2026

An Ozempic injection pen; Ozempic contains semaglutide, the same medicine as Wegovy

HualinXMN / Wikimedia Commons, CC BY-SA 4.0 (cropped)

A study published Nov. 16, 2026, found that weekly semaglutide lowered body mass index in children ages 6 to 11 with obesity. The trial also found smaller height gains among children receiving the medicine than among those given a placebo.

Wegovy is not approved in the United States for weight management in children younger than 12. Here is what the trial found and what remains unresolved.

What Did the Trial Test?

The STEP Young study was a phase 3, double-blind, randomized, placebo-controlled trial funded by Novo Nordisk. It included 167 children with obesity, with 112 assigned to semaglutide and 55 to placebo.

Participants received weekly injections for 104 weeks, followed by seven weeks without the study medicine. Both groups received lifestyle counseling.

According to Novo Nordisk, more than 85% of the children had class II or III severe obesity when the trial began. That detail limits how broadly the findings can be applied to other children.

Two hands holding out a yellow tape measure
ElisaRiva / Pixabay

How Did BMI and Height Change?

At week 68, average BMI had decreased 13.5% in the semaglutide group and increased 2.7% in the placebo group, according to the study. At the same point, 38% of participants receiving semaglutide had a BMI below the obesity threshold for their age and sex, compared with 2% of those receiving placebo.

Height gains were smaller in the semaglutide group. Median gains at week 68 were 5.7 centimeters with semaglutide and 7.8 centimeters with placebo. By week 104, the corresponding gains were 8.8 centimeters and 12.1 centimeters.

Researchers also reported lower average annual height velocity with semaglutide. Changes in bone age, bone mineral density, and observed stages of puberty were similar between the groups.

What Did the Safety Results Show?

Novo Nordisk said the trial identified no safety concerns involving growth or pubertal development. However, the study covered 104 weeks of treatment and a seven-week period without the study medicine, leaving questions that require longer follow-up.

Adverse events were reported in 96% of participants receiving semaglutide and 93% of those receiving placebo. Gastrointestinal problems were the most common, and one participant in the semaglutide group stopped treatment because of them.

By week 111, vomiting had been reported in 70% of the semaglutide group and 29% of the placebo group. Diarrhea was reported in 62% and 35%, respectively, while nausea was reported in 58% and 24%.

The curved Novo Nordisk headquarters building stands behind a blue company sign.
Novo Nordisk’s headquarters building in Bagsværd, Denmark, in June 2016. News Øresund / Wikimedia Commons, CC BY 3.0 (cropped)

Is Wegovy Approved for Younger Children?

No. The FDA expanded Wegovy’s weight-management indication to patients ages 12 and older with obesity in December 2022. The current prescribing information says its safety and effectiveness for long-term weight reduction have not been established in patients younger than 12.

Novo Nordisk described the semaglutide injection tested in STEP Young as investigational for children younger than 12 and said it is not approved in the United States for that age group. The trial results do not change the approved label.

The difference in height gains and the limits of the trial’s follow-up are likely to remain central to the discussion. What questions would you want researchers to answer next?

Follow The HyperHive on MSN for more stories like this.

Sources:

Rinor

Share